Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solrikitug Phase 1 in Healthy Participants
NCT06640920Phase 1Completed
- Start
- Apr 2024
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of solrikitug in eosinophilic esophagitis (EoE), asthma and chronic obstructive pulmonary disease (COPD) (4 cohorts). Primary endpoint: Safety and tolerability at 140 days. Started Apr 2024; status: completed.
02
Drugs
solrikitug
03
Conditions
eosinophilic esophagitis (EoE)asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06640920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640920.